Skip to main content
. 2017 Jul 26;12(7):e0181758. doi: 10.1371/journal.pone.0181758

Table 4. Metabolites with significant difference between the control and the disease activity of NMOSD (C, healthy control; RL, relapse; RM, Remission).

Metabolite Multiple comparison (adjusted p-value*) FDR*** Metabolic change**** Mean (SD) of group(mM)
RL RM C RL RM
2-hydroxybutyrate **RL-C(<0.001) RM-C(<0.001) <0.05 <0.05 Δ Δ 0.0420 (0.0086) 0.0757 (0.0437) 0.0697 (0.0303)
Acetone RL-C(<0.001) RM-C(0.001) <0.05 <0.05 Δ Δ 0.1112 (0.0364) 0.2125 (0.0760) 0.2188 (0.0387)
Formate RL-C(0.003) RM-C(0.004) 0.019 0.018 Δ Δ 0.0449 (0.0061) 0.0579 (0.0168) 0.0582 (0.0252)
Pyroglutamate RL-C(0.006) RM-C(<0.001) <0.05 <0.05 Δ Δ 0.0332 (0.0030) 0.0426 (0.0142) 0.0437 (0.0080)
Acetate C-RL(<0.001) C-RM(0.001) <0.05 <0.05 0.2993 (0.0331) 0.2460 (0.0393) 0.2732 (0.0306)
Glucose C-RL(0.001) C-RM(0.002) <0.05 <0.05 4.5681 (0.2540) 3.9866 (0.8970) 4.3001 (1.1814)
Lactate RL-C(<0.001) RM-C(0.002) <0.05 <0.05 Δ Δ 1.8832 (0.1715) 2.5498 (0.8466) 2.3316 (1.1543)
Isoleucine RL-C(0.006) RM-C(0.002) <0.05 <0.05 Δ Δ 0.0079 (0.0013) 0.0112 (0.0056) 0.01188 (0.0062)

* Adjusted p-value was calculated by Bonferroni’s correction.

** C, healthy control; RL, relapse; RM, Remission

*** FDR was calculated by Benjamini-Hochberg method.

**** Compared to the values of healthy controls, Δ indicates increase and ∇ indicates decrease.